Analyst Research Roundup: Houston American Energy Corp. (HUSA), Lipocine Inc. (LPCN)

Houston American Energy Corp. (NYSE:HUSA) tinted gains of +3.68% (+0.01 points) to US$0.21. The volume of 0.25 Million shares climbed down over an trading activity of 276.85 Million shares. EPS ratio determined by looking at last 12 month figures is -0.01. Over the same time span, the stock marked US$0.47 as its best level and the lowest price reached was US$0.17. The corporation has a market cap of US$12.28 Million.

Houston American Energy Corp. (NYSE:HUSA)’s earnings per share has been growing at a 51.9 percent rate over the past 5 year when average revenue increase was noted as 8.9 percent. The return on equity ratio or ROE stands at -10.6 percent while most common profitability ratio return on investment (ROI) was -25.7 percent. The company’s institutional ownership is monitored at 3.9 percent. The company’s net profit margin has achieved the current level of -34 percent and possesses 61.5 percent gross margin.

Lipocine Inc. (NASDAQ:LPCN) is worth US$35 Million and has recently risen 3.68% to US$1.69. The latest exchange of 0.29 Million shares is below its average trading activity of 599.22 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$2.64 while the mean 12-month price target for the shares is US$7.63.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 3.07, and a price to sales ratio of 87.5. For the past 5 years, the company’s revenue has grown 0%, while the company’s earnings per share has grown 29.8%. With an institutional ownership near 12.3%, it carries an earnings per share ratio of -0.03.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 1 brokerage firms polled by Factset Research. At present, 1 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.